Human research · RCT
Jiang Y et al., Ophthalmology, 2022
Landmark T02 #1, main finding. In a 12-month multicentre randomised controlled trial in Chinese children aged 8-13 with low-to-moderate myopia, adding repeated low-level red-light (RLRL) therapy - a desktop device emitting 650 nm red light, 3 minutes per session, twice a day, 5 days a week - to single-vision spectacles (SVS) slowed eye growth over one year. Adjusted 12-month axial elongation (the pre-registered primary outcome) was 0.13 mm with RLRL vs 0.38 mm with SVS; between-group difference 0.26 mm (95% CI 0.20-0.31; P<0.001), a 69.4% reduction. Myopia (SER) progressed -0.20 D vs -0.79 D, difference 0.59 D (95% CI 0.46-0.72; P<0.001), a 76.6% reduction. No severe adverse events, no loss of best-corrected vision, and no OCT structural damage were observed among the children scanned.
Source: Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial. Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, Zhang J, Xiong R, Yuan Y, Zeng J, Morgan IG, He M. Ophthalmology. 2022;129(5):509-519. doi:10.1016/j.ophtha.2021.11.023. PMID 34863776. Published online 2021-12-01. ClinicalTrials.gov NCT04073238.
Verified research card EL-LM-T02-01-a-R1